Compare Cytokinetics Inc (CYTK) vs Sumitomo Mitsui Financial Group Inc Unsponsored American Depositary Shares (Japan) (SMFG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Sumitomo Mitsui Financial Group Inc Unsponsored American Depositary Shares (Japan) — how do they compare? Cytokinetics Inc trades at $61.95 (market cap $8.62B), while Sumitomo Mitsui Financial Group Inc Unsponsored American Depositary Shares (Japan) trades at $24.84 (market cap $156.97B). The key difference: Sumitomo Mitsui Financial Group Inc Unsponsored American Depositary Shares (Japan) is far larger — about 18.2× Cytokinetics Inc's market cap, and Sumitomo Mitsui Financial Group Inc Unsponsored American Depositary Shares (Japan) pays a 2.34% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and Sumitomo Mitsui Financial Group Inc Unsponsored American Depositary Shares (Japan) for 0 Days on average.
| CYTK | SMFG | |
|---|---|---|
Market Cap | $8.62B | $156.97B |
Volume | 2,594,626 | 1,237,125 |
Sector | Health | Financials |
52-Week High | $87.26 | $27.56 |
52-Week Low | $54.76 | $15.20 |
Typical Hold Time | 19 Days | 0 Days |
Enterprise Value | $8.72B | $12.48T |
Dividend Yield | — | 2.34% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cytokinetics (CYTK) trades at $61.12, down 0.37% on the day, with a bearish technical signal from moving averages despite some oversold RSI readings. The company reported a net loss of $784.96 million on $88.04 million revenue in 2025, with a negative net income margin of -1,321.12% in 2026. Recent news highlights clinical progress for aficamten in hypertrophic cardiomyopathy and executive stock sales.
Wall Street maintains strong bullish sentiment with a 97.14% buy rating and $112.60 consensus price target, but high cash burn, persistent losses, and insider selling pose significant risks. The stock's outlook hinges on successful commercialization of its heart failure pipeline amid substantial financial and competitive pressures.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Sumitomo Mitsui Financial Group Inc Unsponsored American Depositary Shares (Japan)
Sumitomo Mitsui Financial Group is a Japanese financial services company with banking, securities, leasing, and asset management businesses. It serves retail, corporate, and institutional clients.
Read more on SMFG →
